

Issue 34: February 2026

More approvals than setbacks this month

This newsletter summarises final decisions from HTA bodies around the world from published reports in February 2026.

Good news for: **Cefiderocol**, approved for urinary tract and hospital-acquired pneumonia in Korea; **Resmetirom**, approved for steatohepatitis in France; and **Vimseltinib**, approved for synovial giant cell tumours in France and Germany.

Mixed news for: **Daratumumab**, approved in Germany for newly-diagnosed multiple myeloma but not approved for smoldering myeloma; and patients with graft-versus-host disease, with **belumosudil** approved in Korea but **ruxolitinib** not approved in England and exempt from submission in Wales.

Bad news for: **Avapritinib**, not approved in Germany for gastrointestinal stromal tumours, advanced or indolent systemic mastocytosis; **Donanemab**, not approved for early Alzheimer's dementia in Scotland and Germany; and **Lecanemab**, not approved for early Alzheimer's dementia in Germany.

“
38 Approvals
15 with special arrangements
2 with orphan drug status

“
32 Not approved
5 Excluded
3 Terminated

“
6 Evidence reviews

HTANGEL

Issue 34: February 2026

Pharmacological Technologies



Brazil
CONITEC

Blood
Beta-thalassaemia
LUSPATERCEPT

Not approved



Brazil
CONITEC

Cancer
Acute myeloid
leukaemia
VENETOCLAX

Not approved



Brazil
CONITEC

Blood
Haemophilia A
EMICIZUMAB

Not approved



Germany
IQWiG G25-32

Cancer
Astrocytoma,
Oligodendroglioma
VORASIDENIB

Approved
orphan drug
status



Germany
IQWiG A25-139

Blood
Myelofibrosis
MOMELOTINIB

Not approved



Brazil
CONITEC

Cancer
Basal cell carcinoma
VISMODEGIB

Not approved



Wales
AWTTC OW36

Cancer
Acute myeloid
leukaemia
GILTERITINIB

Approved
with special
conditions



Wales
AWTTC 5254

Cancer
Bladder cancer
DURVALUMAB

Excluded



HTANGEL

Issue 34: February 2026

Pharmacological Technologies



England
NICE TA1136

Cancer
Colorectal cancer
BEVACIZUMAB



England
NICE TA1127

Cancer
Lung cancer
NIVOLUMAB



Wales
AWTTC 6720

Cancer
Colorectal cancer
BEVACIZUMAB



England
NICE TA1133

Cancer
Multiple myeloma
BELANTAMAB MAFODOTIN,
POMALIDOMIDE,
DEXAMETHASONE



France
HAS AP552

Cancer
Gastroesophageal
junction cancer
TRASTUZUMAB
DERUXTECAN



Germany
IQWiG A26-02

Cancer
Multiple myeloma
DARATUMUMAB



Germany
IQWiG A25-138

Cancer
Gastrointestinal
stromal cancer
AVAPRITINIB



Germany
IQWiG A25-108

Cancer
Multiple myeloma
DARATUMUMAB



HTANGEL

Issue 34: February 2026

Pharmacological Technologies



Germany
IQWiG A25-109

Cancer
Multiple myeloma
DARATUMUMAB

Not approved



Germany
IQWiG G25-31

Cancer
Tenosynovial giant cell tumour
VIMSELTINIB

Approved orphan drug status



England
NICE TA1129

Cancer
Ovarian cancer, Fallopian tube cancer, Peritoneal cancer
NIRAPARIB

Approved with special conditions



Brazil
CONITEC

Cardiovascular
Anti-neutrophil cytoplasmic autoantibody-associated vasculitis
CYCLOPHOSPHAMIDE

Not approved



England
NICE TA1130

Cancer
Prostate cancer
TALAZOPARIB,
ENZUALITAMIDE

Approved with special conditions



Brazil
CONITEC

Cardiovascular
Anti-neutrophil cytoplasmic autoantibody-associated vasculitis
RITUXIMAB, MYCOPHENOLATE MOFETIL,
AZATHIOPRINE, METHOTREXATE,
CYCLOPHOSPHAMIDE

Not approved



France
HAS AP556

Cancer
Synovial giant cell tumour
VIMSELTINIB

Approved



Canada
CDA RC1590

Cardiovascular
Heart failure
FERRIC
DERISOMALTOSE

Not approved



HTANGEL

Issue 34: February 2026

Pharmacological Technologies



France
HAS AP558

Cardiovascular
Hereditary
angioedema
SEBETRAL STAT



Korea
HIRA 2026-24

Endocrine
Type 2 diabetes
mellitus
DIABETIC SOLVENTS



Scotland
SMC 2831

Cardiovascular
Pulmonary arterial
hypertension
SOTATERCEPT



Korea
HIRA 2026-24

Endocrine
Type 2 diabetes
mellitus
SEMAGLUTIDE



England
NICE TA1137

Endocrine
Type 2 diabetes
mellitus
CANAGLIFLOZIN



Korea
HIRA 2026-24

Gastrointestinal
Hepatic encephalopathy
L-ORNITHINE-L-
ASPARTATE



Wales
AWTTC 5397

Endocrine
Type 2 diabetes
mellitus
CANAGLIFLOZIN



France
HAS AP545

Gastrointestinal
MASH
steatohepatitis
RESMETIROM



HTANGEL

Issue 34: February 2026

Pharmacological Technologies



Brazil
CONITEC

Genetic & Metabolic
Achondroplasia
VOSORITIDE

Not approved



Germany
IQWiG A25-146

Genetic & Metabolic
Plexiform neurofibromas
SELUMETINIB

Not approved



Germany
IQWiG A25-144

Genetic & Metabolic
Hereditary transthyretin amyloidosis
DIFLUNISAL

Not approved



Korea
HIRA 2026-24

Genetic & Metabolic,
Musculoskeletal
Osteoporosis, Parathyroid dysfunction
CALCIUM AND VITAMIN D

Approved



England
NICE HST34

Genetic & Metabolic
Neuronal ceroid lipofuscinosis type 2
CERLIPONASE ALFA

Not approved



Korea
HIRA 2026-24

Infection
Bacterial infection
AMPICILLIN,
SULBACTAM


Approved



Germany
IQWiG A25-147

Genetic & Metabolic
Plexiform neurofibromas
SELUMETINIB

Not approved



Korea
HIRA 2026-24

Infection
Bacterial infection
CEFIDEROCOL

Approved



HTANGEL

Issue 34: February 2026

Pharmacological Technologies



Brazil
CONITEC

Infection
Chlamydia, Syphilis
DOXYCYCLINE

Approved



Wales
AWTTC 8048

Infection
Influenza
BALOXAVIR
MARBOXIL

Excluded



Canada
CDA HC0118

Infection
Clostridioides
difficile
FIDAXOMICIN

Approved



England
NICE TA1135

Infection
Influenza
BALOXAVIR
MARBOXIL

Terminated



England
NICE TA1056

Infection
COVID-19
MOLNUPIRAVIR

Approved



Brazil
CONITEC

Infection
Respiratory syncytial
virus
NIRSEVIMAB

Approved



England
NICE TA878

Infection
COVID-19
NIRMATRELVIR, RITONAVIR,
TOCILIZUMAB

**Approved
with special
conditions**



Scotland
SMC 2862

Mental Health
Depression
ZURANOLONE

**Not
approved**



HTANGEL

Issue 34: February 2026

Pharmacological Technologies



Korea
HIRA 2026-24

Musculoskeletal
Osteoarthritis
SODIUM HYALURONATE,
HEXAMETHYLENEDIAMINE

Approved



Brazil
CONITEC

Musculoskeletal
Osteoporosis
ROMOSOZUMAB,
TERIPARATIDE

Not approved



Scotland
SMC 2871

Neurology
Alzheimer's disease
DONANEMAB

Not approved



Germany
IQWiG A25-134

Neurology
Alzheimer's disease
DONANEMAB

Not approved



Germany
IQWiG A26-01

Neurology
Alzheimer's disease
LECANEMAB

Not approved



Germany
IQWiG A25-111

Neurology
Alzheimer's disease
LECANEMAB

Not approved



Brazil
CONITEC

Neurology
Amyotrophic Lateral
Sclerosis
EDARAVONE

Not approved



France
HAS AP548

Neurology
Chronic inflammatory
demyelinating
polyradiculoneuritis
EFGARTIGIMOD ALFA

Not approved



HTANGEL

Issue 34: February 2026

Pharmacological Technologies



France
HAS AP551

Neurology
Friedreich's ataxia
OMAVELOXOLONE

Approved



England
NICE TA1132

Other
Graft-versus-host
disease
RUXOLITINIB

Terminated



Brazil
CONITEC

Neurology
Huntington's disease
DEUTETRABENAZINE

Not
approved



Brazil
CONITEC

Other
Poisoning
MESO-2,3-
DIMERCAPTOSUCCINIC
ACID

Approved



Korea
HIRA 2026-24

Other
Graft-versus-host
disease
BELUMOSUDIL

Approved



Germany
IQWiG A25-137

Other
Systemic
mastocytosis
AVAPRITINIB

Not
approved



Wales
AWTTC 9500

Other
Graft-versus-host
disease
RUXOLITINIB

Excluded



Germany
IQWiG A25-136

Other
Systemic
mastocytosis
AVAPRITINIB

Not
approved



HTANGEL

Issue 34: February 2026

Pharmacological Technologies



England
NICE TA1131

Renal

Lupus nephritis

OBINUTUZUMAB,
MYCOPHENOLATE MOFETIL



Germany
IQWiG A25-145

Respiratory

Chronic
rhinosinusitis
TEZEPELUMAB



England
NICE TA1128

Renal

Nephropathy
BUDESONIDE



Wales
AWTTC OW34

Respiratory
Pneumonitis
INFLIXIMAB



England
NICE HTG736

Respiratory

Chronic obstructive
pulmonary disease

DIGITAL TECHNOLOGIES



England
NICE TA1134

Respiratory

Chronic
rhinosinusitis

DUPILUMAB



HTANGEL

Issue 34: February 2026

Non-pharmacological Technologies



England
NICE HTG770

Cardiovascular
Bradyarrhythmias
LEADLESS CARDIAC
PACEMAKER
IMPLANTATION

Approved
with special
conditions



England
NICE HTG769

Cardiovascular
Heart failure
PULMONARY ARTERY
PRESSURE TECHNOLOGIES

Not
approved



England
NICE HTG771

Cardiovascular
Symptomatic severe
tricuspid regurgitation
TRANSCATHETER TRICUSPID
VALVE IMPLANTATION

Approved
with special
conditions



Brazil
CONITEC

Ear
Hearing loss
MIDDLE EAR IMPLANT

Not
approved



Scotland
SHGT

Other
Pain
SPECIALIST
INTERVENTIONS

Approved

HTANGEL

Issue 34: February 2026

Diagnostic Testing



Korea
HIRA 2026-24

Cardiovascular
Coagulation function
COAGULATION FUNCTION
BASIC TEST-ACTIVATED
PARTIAL THROMBOPLASTIN
TIME



Korea
HIRA 2026-24

Other
NR
TOTAL IMMUNOGLOBULIN E
ASSAY



Brazil
CONITEC

Skin
Neonatal skin
maturity
OPTICAL READER



HTANGEL

Issue 34: February 2026

Other Guidance



USA
AHRQ

Blood
Haemorrhagic shock
BLOOD TRANSFUSION



Ireland
HIQA

Other
NR
EARLY WARNING
SYSTEMS



Germany
IQWiG E24-02

Cardiovascular
Coronary artery disease
CARDIAC MAGNETIC
RESONANCE IMAGING



Canada
CDA HC0096

Other
Pain
HYDROMORPHONE



Germany
IQWiG D25-01

Eye
Diabetic retinopathy
FUNDUS
PHOTOGRAPHY



Ireland
HIQA

Genetic & Metabolic
Familial
hypercholesterolaemia
POPULATION-BASED
SCREENING




HTANGEL

Issue 34: February 2026

Further Information

HTAngel is designed to help keep you up to date with the latest HTA decisions around the world. Below is a breakdown of the tiles in the newsletter.



At Crystallise we aim to provide an innovative approach to processing information, using software tools to automate processes that are slower and less accurate when done by humans. Our approach provides clients with greater transparency and scope than they could find for the same budget elsewhere. We work with a network of experts and organisations that help us support clients efficiently and effectively, and are proud of our flexible and ingenious way of solving their problems.

For further information about HTAngel contact newsletter@crystallise.com

To speak to us about our services contact contact@crystallise.com

